Clinical Topics
News
Rare, serious alemtuzumab adverse events emerge
New reports reveal rare adverse events in the treatment of relapsing-remitting multiple sclerosis using alemtuzumab.
Article
Siponimod May Benefit Patients With Secondary Progressive MS
Among patients with secondary progressive multiple sclerosis (MS), siponimod appears to decrease the risk of disability progression, according to...
Article
Are Complementary and Alternative Treatments Effective for MS?
Cannabis extract, physical activity, and cognitive behavioral therapy are complementary and alternative medicines (CAMs) with the strongest...
News
Frankincense extract may reduce disease activity in relapsing-remitting MS
Safety results and potential efficacy point to possible future clinical development.
News
Siponimod trial ‘first’ to show delayed disability in secondary progressive MS
But the absolute difference in the rate of confirmed disability progression versus placebo was small.
News
MRI finds PML in some natalizumab-treated patients despite negative CSF, no symptoms
Correlation also observed between viral load and lesion volume.
Conference Coverage
Alemtuzumab-induced autoimmunity: getting closer to answers
Researchers are getting closer to identifying MS patients more susceptible to secondary autoimmunity after alemtuzumab treatment.
Conference Coverage
High dose of novel compound for relapsing-remitting MS shows promise
SAN DIEGO – Evidence of remyelination observed at 24 weeks.
Article
ECTRIMS and EAN Publish Recommendations for Treating MS
The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the European Academy of Neurology (EAN) have published a...
Conference Coverage
Fingolimod switch from an injectable linked to improved outcomes in relapsing MS
SAN DIEGO – The benefit of the switch was observed regardless of previous treatment status.
